Avextra is a biopharmaceutical company based in the German state of Hesse. Our roots are in the German phyto-pharmaceutical industry. As experts in botanical medicines, we believe in the therapeutic potential of the cannabis plant.
Highlights from 2022
Avextra is just getting started
Join us in looking back on an exciting year. We look forward to continuing our success story in the coming year. Be sure to keep up to date with the latest developments on our website.
The Avextra Alliance for Evidence-Based Cannabis-Medicine
- Focused on collaborating with researchers, doctors and scientific associations
- To generate real world patient data in medical cannabis access programs
- With the aim of designing robust clinical trials for proprietary Cannabis-based medicines that can achieve regulatory approval
Mastery of the Full Value Chain
Cultivation in Portugal
In our Portuguese facility, we breed and cultivate selected cannabis genetics that produce exceptional outcomes in extraction and further pharmaceutical manufacturing.
GMP Manufacturing in Germany
Our products are manufactured in a remarkable facility in the center of Germany’s pharmaceutical manufacturing hub. Our exclusive partner has designed and constructed this state-of-the-art manufacturing site exclusively for the production of cannabis-based medicines.
Highest Quality Standard
This is the guarantee for our exceptional product quality.
Avextra collaborates with researchers and healthcare professionals to collect and aggregate real world patient data and RCTs to inform and support regulatory filings.
Cannabis-based medicines that combine innovation and tradition. Avextra is a young company with deep roots in plant-based medicines and the science of botanical extraction. Our focus is on innovation in research and in phyto-pharmaceutical manufacturing.
Dr. Babel has more than 15 years of international experience in Regulatory Affairs & Business Development. Before founding Avextra, he was a partner at McKinsey and CEO at Risk Dynamics.
Dr. Bernhard Babel
During his career in the financial services sector, Neil Smith has held various senior positions and served as Chief Operating Officer for Deutsche Bank. Neil is also a member of various boards in the technology sector.
As Managing Director of Dr. Reckeweg & Co. GmbH, David has many years of experience in herbal medicine as well as global business development. He has been President of the European Coalition on Homeopathic & Anthroposophic Medicinal Products since 2019.
Marla Luther has many years of experience in the field of cannabis-based medicine. As Managing Director of Tilray from 2016 to 2019, she successfully launched the first standardised cannabis extracts in Europe. She has also advised companies, authorities and investors on the implementation and regulation of the industry.
Estela is an EU Qualified Person with the role of Avextra’s Global Head of Quality and technical director of the Portuguese project, joining to the company at 2019. Pharmacis by training with MsC in Toxicology, she has more than 10 years’ experience in QM and Regulatory Affairs. Former production lead at Novartis.
Global QM Head
Before joining Avextra, Sabrina Hüther worked in the QA/QC department at Merck for over 15 years. Sabrina Hüther has a total of more than 20 years of professional experience in the industrial pharmaceutical environment and has already worked for companies such as Sandoz, BC Biochemie and Aventis.
Head of Quality Management
Alin Dumitrescu-Dragan has significant international experience in Risk Management & Business Development. Before joining Avextra, Alin worked for 10 years with Mckinsey and Company in the pharmaceutical and financial sectors.
Head Business Development
Dr Brita Kaltenbrunner is a seasoned professional in HR and regulatory/government affairs, with over 20 years of experience in the healthcare and pharmaceutical industries. With a broad international background across several sectors, including EU and government/public sector, research and the pharma industry, Brita brings a wealth of expertise to her work.
Senior Advisor, HR
Dr. Jakas has more than 20 years of international experience in the field of Banking and Finance with exposure to treasury and investment banking areas at Deutsche Bank.
Dr. Vicente Jakas
Mike Kindrat is a seasoned expert in the cannabis industry, specializing in infrastructure, operations, and product development. He boasts an impressive track record of completing various global infrastructure projects and successfully launching SKUs in well-established markets worldwide.
Managing Director, Southern Europe
Ana is an accomplished executive in Pharmaceutical and Biotechnology, with extensive experience in medical cannabis. She was previously Global Pharma Head and Managing Director at Clever Leaves and held positions at Pfizer, Sanofi, and Merck. As Head of Drug Development at Avextra, Ana leads research efforts.
Ana Maria Serrato
Head of Drug Development
Dr. Gerken is an entrepreneur and was until recently a senior partner at McKinsey, where he worked for almost 30 years. There he established and led global risk management and advised clients from various industries.
Dr. Arno Gerken
Max Wigram has been a successful entrepreneur for more than three decades and joined Avextra in early 2020. He has extensive experience in sales strategy and branding.
Sales strategy and branding
Luís Quaresma is a partner at Iberis Capital in Lisbon. Previously, he founded the investment fund Oxy Capital. Before moving into the investment sector, he worked in the consulting industry at Bain & Co and Boston Consulting Group.
Partner at Iberis Capital
As CEO of Etain Health, Amy Peckham has extensive experience in the US cannabis industry. Etain is a leading medical company based in New York with regard to cultivation, production and patient support in clinics.
CEO from Etain Health
WHaT MaKES US UNIQUE
Made in Germany
Our products are manufactured in a state-of-the-art facility that is fully licenced and continuously monitored by German pharmaceutical regulatory bodies.
Even though the use of cannabis-based medicines is expanding across many geographies, there is still much to discover and learn through targeted investigation.
Research begins with the determination to understand
In close collaboration with prescribing physicians and leading research institutions today we are making a contribution to expand the body of knowledge on the therapeutic potential of the cannabis plant so that in future more cannabis based medicines will be available to address unmet patient needs.
Eurox has rebranded as Avextra
Produkteinführung in Deutschland
Genehmigung zur Eröffnung einer Medizinal-Cannabis-Klinik in England
Herstellungserlaubnis für Cannabis, Deutschland
Vertriebslizenz in Deutschland, Beginn des Verkaufs von cannabis-basierten Arzneimitteln